Nicotinic Acetylcholine Receptors (nAChR) respond to acetylcholine as well as nicotine. This antibody can be used to map structural features on the surface of the acetylcholine molecule relevant to the aspect of its function as a neurotransmitter receptor. Acetylcholine receptor plays a role as an immunogen and antigen in the autoimmune disease Myasthena Gravis (MG). Anti-nAChR is also useful in the research of Alzheimer’s disease and other neurodegenerative diseases.
mAb35-SAP eliminates cells expressing the nicotinic acetylcholine receptors (nAChR). All other cells are left untouched.
The following control is recommended for validating the specificity of the beta conjugate: Rag IgG-SAP (Cat. #IT-17).
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.